1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 11, 1995
NU-TECH BIO-MED, INC.
-------------
(Exact Name of Registrant as specified in charter)
Delaware 0-11772 25-1411971
---------------------------------------------------------------------
(State or other jurisdic- (Commission (IRS Employer
tion of incorporation) File Number) Identification No.)
55 Access Road, Warwick, Rhode Island 02886
---------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (401) 732-6520
---------------------------------------------------------------------
(Former name or former address, if changed since last report.)
2
ITEM 5. OTHER EVENTS.
Listing of Common Stock on the Boston Stock Exchange
On August 11, 1995, the Common Stock of the Company was listed for
trading on the Boston Stock Exchange under the symbol "NTB".
Clinical Trials Agreement
On August 14, 1995, Analytical Biosystems Corporation ("ABC"), a
wholly-owned subsidiary of the Company, entered into an agreement (the "Clinical
Trials Agreement") with a research institution (the "Institution") and certain
individuals (the "Principal Investigators").
The Clinical Trials Agreement relates to the conduct and performance of
certain proprietary research and development activities to be performed and/or
coordinated on a work for hire basis on behalf of ABC by the Institution. The
protocol for which the clinical trials are to be conducted is entitled "A
Randomized Trial Comparing Empiric Therapy Versus Chemotherapy Directed by In
Vitro Sensitivity Testing in Patients with Carcinoma of Unknown Primary Site".
The conduct of the clinical trials is under the exclusive direction and control
of the Institution and the Principal Investigators, who will coordinate the
protocol with participating physicians, manage the project, collect and
correlate data and provide ABC with a final report of the study in form and
content generally accepted by medical and scientific publications and journals.
The Principal Investigators are to direct the study in accordance with
applicable Institution policies and are in accordance with generally accepted
standards of good clinical practice, and all applicable local, state and federal
laws and regulations governing the performance of clinical investigations.
The total approximate cost to ABC is not to exceed $568,000. ABC may
terminate the Clinical Trials Agreement with the Institution at any time, in
which case it is responsible for a payment to the Institution on the basis of
the number of patients evaluated through the date of termination. The clinical
trials being conducted are non-mandatory and are part of the Company's objective
of obtaining correlated data with respect to evaluated patients with respect to
whom treatment has been determined with the aid of the FCA. The cost of the
funding of such clinical trials was an anticipated use of proceeds received from
the Company's December 20, 1994 public offering. It is anticipated that the
clinical trials will commence on or about October 16, 1995 and will be completed
approximately one year thereafter.
2
3
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibits.
Exhibit No. Description of Exhibit
----------- ----------------------
10.1 Redacted copy of Clinical Trials
Agreement dated August 14, 1995
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
----------------------------
J. Marvin Feigenbaum
Chairman of the Board,
President, Chief Executive
and Chief Financial Officer
Dated: August 17, 1995
3
4
EXHIBIT INDEX
-------------
Exhibit No. Description Page No.
----------- ------------- -------
EX-10.1 Redacted copy of Clinical Trials Agreement